184 related articles for article (PubMed ID: 16788380)
1. Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab.
Zhang W; Gordon M; Press OA; Rhodes K; Vallböhmer D; Yang DY; Park D; Fazzone W; Schultheis A; Sherrod AE; Iqbal S; Groshen S; Lenz HJ
Pharmacogenet Genomics; 2006 Jul; 16(7):475-83. PubMed ID: 16788380
[TBL] [Abstract][Full Text] [Related]
2. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab.
Zhang W; Gordon M; Schultheis AM; Yang DY; Nagashima F; Azuma M; Chang HM; Borucka E; Lurje G; Sherrod AE; Iqbal S; Groshen S; Lenz HJ
J Clin Oncol; 2007 Aug; 25(24):3712-8. PubMed ID: 17704420
[TBL] [Abstract][Full Text] [Related]
3. Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab.
Lurje G; Nagashima F; Zhang W; Yang D; Chang HM; Gordon MA; El-Khoueiry A; Husain H; Wilson PM; Ladner RD; Mauro DJ; Langer C; Rowinsky EK; Lenz HJ
Clin Cancer Res; 2008 Dec; 14(23):7884-95. PubMed ID: 19047118
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer.
Dahan L; Norguet E; Etienne-Grimaldi MC; Formento JL; Gasmi M; Nanni I; Gaudart J; Garcia S; Ouafik L; Seitz JF; Milano G
BMC Cancer; 2011 Nov; 11():496. PubMed ID: 22117530
[TBL] [Abstract][Full Text] [Related]
5. Molecular determinants of cetuximab efficacy.
Vallböhmer D; Zhang W; Gordon M; Yang DY; Yun J; Press OA; Rhodes KE; Sherrod AE; Iqbal S; Danenberg KD; Groshen S; Lenz HJ
J Clin Oncol; 2005 May; 23(15):3536-44. PubMed ID: 15908664
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor (EGF) A61G polymorphism and EGF gene expression in normal colon tissue from patients with colorectal cancer.
Spindler KL; Nielsen JN; Ornskov D; Brandslund I; Jakobsen A
Acta Oncol; 2007; 46(8):1113-7. PubMed ID: 17851837
[TBL] [Abstract][Full Text] [Related]
7. The influence of cyclin D1 A870G polymorphism on colorectal cancer risk and prognosis in a Turkish population.
Yaylim-Eraltan I; Arikan S; Yildiz Y; Cacina C; Ergen HA; Tuna G; Görmüs U; Zeybek U; Isbir T
Anticancer Res; 2010 Jul; 30(7):2875-80. PubMed ID: 20683026
[TBL] [Abstract][Full Text] [Related]
8. Associations between genetic polymorphisms of epidermal growth factor receptor (EGFR) and survival of colorectal cancer (CRC) patients treated with 5-fluorouracil-based chemotherapy.
Lai CY; Sung FC; Hsieh LL; Tang R; Chiou HY; Wu FY; Yeh CC
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S599-606. PubMed ID: 23800895
[TBL] [Abstract][Full Text] [Related]
9. Gene polymorphisms of epidermal growth factor receptor and its downstream effector, interleukin-8, predict oxaliplatin efficacy in patients with advanced colorectal cancer.
Zhang W; Stoehlmacher J; Park DJ; Yang D; Borchard E; Gil J; Tsao-Wei DD; Yun J; Gordon M; Press OA; Rhodes K; Groshen S; Lenz HJ
Clin Colorectal Cancer; 2005 Jul; 5(2):124-31. PubMed ID: 16098254
[TBL] [Abstract][Full Text] [Related]
10. Cyclin D1 (CCND1) A870G gene polymorphism modulates smoking-induced lung cancer risk and response to platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients.
Gautschi O; Hugli B; Ziegler A; Bigosch C; Bowers NL; Ratschiller D; Jermann M; Stahel RA; Heighway J; Betticher DC
Lung Cancer; 2006 Mar; 51(3):303-11. PubMed ID: 16406195
[TBL] [Abstract][Full Text] [Related]
11. Polymorphisms of the epidermal growth factor receptor (EGFR) and survival in patients with advanced cancer of the head and neck (HNSCC).
Stoehlmacher-Williams J; Obermann L; Ehninger G; Goekkurt E
Anticancer Res; 2012 Feb; 32(2):421-5. PubMed ID: 22287728
[TBL] [Abstract][Full Text] [Related]
12. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.
Khambata-Ford S; Garrett CR; Meropol NJ; Basik M; Harbison CT; Wu S; Wong TW; Huang X; Takimoto CH; Godwin AK; Tan BR; Krishnamurthi SS; Burris HA; Poplin EA; Hidalgo M; Baselga J; Clark EA; Mauro DJ
J Clin Oncol; 2007 Aug; 25(22):3230-7. PubMed ID: 17664471
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor intron 1 CA dinucleotide repeat polymorphism and survival of advanced gastric cancer patients treated with cetuximab plus modified FOLFOX6.
Han SW; Oh DY; Im SA; Park SR; Lee KW; Song HS; Lee NS; Lee KH; Choi IS; Lee MH; Kim MA; Kim WH; Bang YJ; Kim TY
Cancer Sci; 2010 Mar; 101(3):793-9. PubMed ID: 20047592
[TBL] [Abstract][Full Text] [Related]
14. K-ras mutations and benefit from cetuximab in advanced colorectal cancer.
Karapetis CS; Khambata-Ford S; Jonker DJ; O'Callaghan CJ; Tu D; Tebbutt NC; Simes RJ; Chalchal H; Shapiro JD; Robitaille S; Price TJ; Shepherd L; Au HJ; Langer C; Moore MJ; Zalcberg JR
N Engl J Med; 2008 Oct; 359(17):1757-65. PubMed ID: 18946061
[TBL] [Abstract][Full Text] [Related]
15. The effect of the cyclin D1 (CCND1) A870G polymorphism on colorectal cancer risk is modified by glutathione-S-transferase polymorphisms and isothiocyanate intake in the Singapore Chinese Health Study.
Probst-Hensch NM; Sun CL; Van Den Berg D; Ceschi M; Koh WP; Yu MC
Carcinogenesis; 2006 Dec; 27(12):2475-82. PubMed ID: 16829689
[TBL] [Abstract][Full Text] [Related]
16. Impact of the cyclin D1 A870G polymorphism on susceptibility to sporadic colorectal cancer in Taiwan.
Huang WS; Tang R; Lin PY; Changchien CR; Chen JS; Chiang JM; Yeh CY; Wang JY; Hsieh LL
Dis Colon Rectum; 2006 May; 49(5):602-8. PubMed ID: 16552496
[TBL] [Abstract][Full Text] [Related]
17. First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD).
Sastre J; Aranda E; Grávalos C; Massutí B; Varella-Garcia M; Rivera F; Soler G; Carrato A; Manzano JL; Díaz-Rubio E; Hidalgo M
Crit Rev Oncol Hematol; 2011 Jan; 77(1):78-84. PubMed ID: 20042346
[TBL] [Abstract][Full Text] [Related]
18. Cetuximab for the treatment of colorectal cancer.
Jonker DJ; O'Callaghan CJ; Karapetis CS; Zalcberg JR; Tu D; Au HJ; Berry SR; Krahn M; Price T; Simes RJ; Tebbutt NC; van Hazel G; Wierzbicki R; Langer C; Moore MJ
N Engl J Med; 2007 Nov; 357(20):2040-8. PubMed ID: 18003960
[TBL] [Abstract][Full Text] [Related]
19. Association of epidermal growth factor receptor polymorphism, skin toxicity, and outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment.
Klinghammer K; Knödler M; Schmittel A; Budach V; Keilholz U; Tinhofer I
Clin Cancer Res; 2010 Jan; 16(1):304-10. PubMed ID: 20028750
[TBL] [Abstract][Full Text] [Related]
20. CyclinD1 and interleukin-1 receptor antagonist polymorphisms are associated with prognosis in neoadjuvant-treated gastric carcinoma.
Stocker G; Ott K; Henningsen N; Becker K; Hapfelmeier A; Lordick F; Hois S; Plaschke S; Höfler H; Keller G
Eur J Cancer; 2009 Dec; 45(18):3326-35. PubMed ID: 19822419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
